Received Feb 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | X4T99 | — |
patient administered a second dose of Menveo; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 14-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number X4T99, expiry date 30-SEP-2025) for prophylaxis. Previously administered products included Menveo (received 1st dose on 20-SEP-2022). On 31-JAN-2025, the patient received the 2nd dose of Menveo. On 31-JAN-2025, an unknown time after receiving Menveo, the patient experienced extra dose administered (Verbatim: patient administered a second dose of Menveo). The outcome of the extra dose administered was unknown. Additional Information: GSK receipt date: 31-JAN-2025 The medical assistant reported that they administered a second dose of Menveo which led to, extra dose administered. The reporter wanted to know advise/safety concerns about this situation. The vaccination date, vaccine detail and patient demographics were obtained from the medical assistant´s end. No further information was obtained in this call. The vaccine administration facility was the same as primary reporter.